DelSiTech Closes EUR 10M Financing Round
Summary
The round was led by DRW Venture Capital, and Tolmar International Ltd, which together contributed more than EUR 9M, and existing investors. Led by CEO Said Lasse Leino, DelSiTech is a technology specialist in biodegradable silica-based controlled release of small molecule drugs, biologics, and vaccines. Silica Matrix is an advanced delivery technology platform for parenteral and local administration of injectable and implant dosage forms as well as eye drops. The proprietary technology is based on silica (SiO ) matrix into which the molecule or therapeutic agent of interest is embedded using a process called sol-gel. This investment, together with our increasing revenues from our own drug development, will help us to reach our strategic business goals and objectives over the next couple of years, as we continue to address high unmet clinical and commercial needs for the benefit of patients.”